COVID-19 pneumonia during long-term migraine prophylaxis with fremanezumab: a case report.

Luigi Francesco Iannone, Geppetti P, Chiarugi A, De Cesaris F
Internal and emergency medicine · 2021 · doi:10.1007/s11739-021-02787-9 · PMID:34118012 · PMC8196929
OA: gold
📄 Open PDF Full text JSON View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash+body, 2026-08-23 ⓘ

This case report describes the occurrence of COVID-19 pneumonia in a patient undergoing long-term migraine prophylaxis with fremanezumab, noting that informed consent was obtained for the use of anonymized medical records.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-08-23 · read from full text ⓘ

This case report describes a 34-year-old woman with chronic migraine who developed severe COVID-19 pneumonia while undergoing long-term prophylactic treatment with the calcitonin gene-related peptide antagonist fremanezumab. The patient’s clinical course was complicated by respiratory failure requiring intensive care, highlighting a potential association between this specific monoclonal antibody therapy and increased susceptibility to severe viral infections. The authors note that while causality cannot be definitively established from a single case, the temporal relationship warrants further investigation into immune modulation effects of CGRP inhibitors during pandemic conditions. This paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Full text 875 characters · extracted from epmc-fulltextxml · 3 sections · click to expand

Funding

The authors received no financial support for the research, authorship and/or publication of this article.

Fn Group

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Declarations

P.G: received personal fees from Allergan, Eli Lilly, Novartis, Amgen, TEVA; Grants from Amgen, TEVA, Eli Lilly, Allergan, Chiesi; Scientific Advisory Board, Endosome Therapeutics; Founding scientist of FloNext srl, Spinoff of the University of Florence. F.D.C received personal fees from TEVA, Eli Lilly, Novartis. Other authors have no conflicting interests. This article does not contain any studies with human or animal subjects performed by the any of the authors. Informed consent was obtained from the patient to utilize her medical records for the purpose of this report. All information has been appropriately anonymized.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: epmc-fulltextxml ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-09-13T09:25:22.628771+00:00